ପାରୋକ୍ସେଟାଇନ

ପାରୋକ୍ସେଟାଇନ
Clinical data
Trade names	Paxil, Seroxat, Loxamine
AHFS/Drugs.com	monograph
MedlinePlus	a698032
data	US DailyMed: Paroxetine;
Pregnancy; category	AU: D ; ;
Routes of; administration	By mouth
Drug class	Selective serotonin reuptake inhibitor (SSRI)
ATC code	N06AB05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Extensively absorbed from the GI tract, but extensive first-pass metabolism in the liver
Protein binding	93–95%
Metabolism	Extensive, hepatic (mostly CYP2D6-mediated)
Elimination half-life	21 hours
Excretion	Renal (64%; 2% unchanged and 62% as metabolites), faecal (36%; <1% unchanged)
Identifiers
	IUPAC name (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine;
CAS Number	61869-08-7 ;
PubChem CID	43815;
IUPHAR/BPS	4790;
DrugBank	DB00715 ;
ChemSpider	39888 ;
UNII	41VRH5220H;
KEGG	D02362 ;
ChEBI	CHEBI:7936 ;
ChEMBL	CHEMBL490 ;
ECHA InfoCard	100.112.096
Chemical and physical data
Formula	C19H20FNO3
Molar mass	୩୨୯.୩୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F;
	InChI InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 ; Key:AHOUBRCZNHFOSL-YOEHRIQHSA-N ;
(what is this?) (verify)

ପାରୋକ୍ସେଟାଇନ, ସିଲେକ୍ଟିଭ୍ ସେରୋଟୋନିନ୍ ରିଅପଟେକ ଇନହିବିଟର (SSRI) ଶ୍ରେଣୀର ଏକ ଆଣ୍ଟିଡିପ୍ରେସାଣ୍ଟ ଯାହା ପ୍ୟାକ୍ସିଲ ଏବଂ ସେରକ୍ସାଟ ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହେଉଛି | ^[୫] ଏହା ପ୍ରମୁଖ ଅବସାଦ ବେମାରୀ,, ଅବସେସିଭ୍-କମ୍ପଲସିଭ ଡିଜଅର୍ଡ଼ର, ପ୍ୟାନିକ୍ ଡିଜଅର୍ଡର୍, ସାମାଜିକ ଉତ୍କଣ୍ଠା ବେମାରୀ, ଜେନେରାଲାଇଜଡ୍ ଚିନ୍ତା ବ୍ୟାଧି ଏବଂ ପ୍ରାକ୍‌ଋତୁସ୍ରାବ ଅସୁଖ ବେମାରୀ ଇତ୍ୟାଦି ରୋଗମାନଙ୍କର ଚିକିତ୍ସାରେ ଦିଆଯାଏ | ^[୫] ଏହା ମଧ୍ୟ ଋତୁବନ୍ଦ ପରେ ଅକାଳ ସ୍ଖଳନ, ଶରୀର ଉସ୍ମତା ନିମନ୍ତେ ଦିଆଯାଏ ।^[୫] ^[୬] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରାହୀନତା, ଶୁଖିଲା ପାଟି, ଅରୁଚି, ଭୋକ ନଷ୍ଟ ହେବା, ଝାଳ ବାହାରିବା, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ଯୌନ‌କ୍ରିୟା ଅସୁବିଧା ଅନ୍ତର୍ଭୁକ୍ତ | ^[୫] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ୨୫ ବର୍ଷରୁ କମ୍ ବୟସରେ ଆତ୍ମହତ୍ୟା, ସେରୋଟୋନିନ୍ ସିଣ୍ଡ୍ରୋମ ଏବଂ ମାନିଆ ହୋଇପାରେ | ^[୫] ଯେତେବେଳେ ଅନ୍ୟ SSRI ଏବଂ SNRI ତୁଳନାରେ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାର ହାର ସମାନ ଦେଖାଯାଏ, ଆଣ୍ଟିଡେପ୍ରେସାଣ୍ଟ ବିଚ୍ଛିନ୍ନତା ସିଣ୍ଡ୍ରୋମ ଅଧିକ ହୋଇପାରେ | ^[୭] ^[୮] ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର ଅପେକ୍ଷାକୃତ ନିରାପଦ ଥିବାବେଳେ ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୯] ରାସାୟନିକ ସେରୋଟୋନିନର ପୁନଃ-ଅପଟେକ୍‌କୁ ମସ୍ତିଷ୍କରେ ଥିବା ନିଉରୋନ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ | ^[୫]

ଚିକିତ୍ସା ପାଇଁ ପାରୋକ୍ସେଟାଇନ୍ ୧୯୯୨ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଅନୁମୋଦିତ ହୋଇଥିଲା ଏବଂ ପ୍ରଥମେ ଗ୍ଲାକ୍ସୋସ୍କିଥକ୍ଲାଇନ କମ୍ପାନୀ ବିକ୍ରି କରିଥିଲେ | ^[୫] ^[୧୦] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ^[୧୧] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସ ଯୋଗାଣ ୨୦୧୯ ସୁଦ୍ଧା ଏନଏଚଏସର ପ୍ରତି ମାସରେ £ ୧.୧୦ ଖର୍ଚ୍ଚ ହୁଏ ।^[୧୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟରେ ପ୍ରାୟ ୨.୪୦ US$ ଖର୍ଚ୍ଚ ହୁଏ । ^[୧୩] ୨୦୧୭ରେ ଏହା ଏକାଦଶ ମିଲିୟନରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ସହିତ ଯୁକ୍ତରାଷ୍ଟ୍ରର ୬୮ ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା | ^[୧୪] ^[୧୫] ଯୁକ୍ତରାଷ୍ଟ୍ରର ନ୍ୟାୟ ବିଭାଗ ୨୦୧୨ରେ ଗ୍ଲାକ୍ସୋ ସ୍ମିଥକାଇନ୍ $ 3 ଜରିମାନା ହୋଇଛି ତଥ୍ୟକୁ ଅଟକାଇବା ପାଇଁ, ୧୮ ବର୍ଷରୁ କମ୍ ବୟସରେ ବ୍ୟବହାରକୁ ବେଆଇନ ଭାବରେ ପ୍ରୋତ୍ସାହିତ କରିବା ପାଇଁ ଏବଂ ବିଲିୟନ, ଏହାର କ୍ଲିନିକାଲ୍ ଟ୍ରାଏଲ୍ ପରେ ଡିପ୍ରେସନ୍ ସହିତ କିଶୋର ଅବସ୍ଥାରେ ପାରାକ୍ସେଟାଇନର ପ୍ରଭାବକୁ ବିଭ୍ରାନ୍ତିକର ଭାବରେ ଜଣାଇବା ପାଇଁ | ^[୧୬] ^[୧୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ Sandoz Pty Ltd (18 January 2012). "Product Information Paroxetine Sandoz 20Mg Film-Coated Tablets" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. Archived from the original on 4 September 2015. Retrieved 22 November 2013.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ Mylan Institutional Inc. (January 2012). "Paroxetine (paroxetine hydrochloride hemihydrate) tablet, film coated". DailyMed. U.S. National Library of Medicine. Archived from the original on 23 October 2013. Retrieved 22 November 2013.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ Sandoz Limited (21 March 2013). "Paroxetine 20 mg Tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Datapharm Ltd. Archived from the original on 3 December 2013. Retrieved 22 November 2013.
↑ "Paxil, Paxil CR (paroxetine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 10 November 2015. Retrieved 22 November 2013.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ ^୫.୬ ^୫.୭ "Paroxetine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
↑ Fischer, Andrea (June 28, 2013). "FDA approves the first non-hormonal treatment for hot flashes associated with menopause" (Press release). Food and Drug Administration. Archived from the original on January 18, 2017.
↑ Hosenbocus S, Chahal R (February 2011). "SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 20 (1): 60–7. PMC 3024727. PMID 21286371.
↑ Pae CU, Patkar AA (February 2007). "Paroxetine: current status in psychiatry". Expert Review of Neurotherapeutics. 7 (2): 107–20. doi:10.1586/14737175.7.2.107. PMID 17286545.
↑ "Paroxetine Pregnancy and Breastfeeding Warnings" (in ଇଂରାଜୀ). Drugs.com. Archived from the original on 3 December 2018. Retrieved 3 March 2019.
↑ Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations – FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011) (in ଇଂରାଜୀ). DrugPatentWatch.com. p. 344. ISBN 9781934899816. Archived from the original on 2019-03-06. Retrieved 2019-03-04.
↑ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 363. ISBN 9780857113382.
↑ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 363. ISBN 9780857113382.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 2020-03-18. Retrieved 11 April 2020.
↑ "Paroxetine - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.
↑ "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data" (Press release). United States Department of Justice, Office of Public Affairs. 2 July 2012. Archived from the original on 9 September 2014. Retrieved 6 October 2015. The United States alleges that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy.
↑ Thomas, Katie; Schmidt, Michael S. (2 July 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times. Archived from the original on 2 March 2017. Retrieved 28 February 2017.

[TGA-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ Sandoz Pty Ltd (18 January 2012). "Product Information Paroxetine Sandoz 20Mg Film-Coated Tablets" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. Archived from the original on 4 September 2015. Retrieved 22 November 2013.

[DM-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ Mylan Institutional Inc. (January 2012). "Paroxetine (paroxetine hydrochloride hemihydrate) tablet, film coated". DailyMed. U.S. National Library of Medicine. Archived from the original on 23 October 2013. Retrieved 22 November 2013.

[EMC-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ Sandoz Limited (21 March 2013). "Paroxetine 20 mg Tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Datapharm Ltd. Archived from the original on 3 December 2013. Retrieved 22 November 2013.

[MSR-4] "Paxil, Paxil CR (paroxetine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 10 November 2015. Retrieved 22 November 2013.

[AHFS2019-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ ^୫.୬ ^୫.୭ "Paroxetine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.

[FDA2013-6] Fischer, Andrea (June 28, 2013). "FDA approves the first non-hormonal treatment for hot flashes associated with menopause" (Press release). Food and Drug Administration. Archived from the original on January 18, 2017.

[ReferenceD-7] Hosenbocus S, Chahal R (February 2011). "SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 20 (1): 60–7. PMC 3024727. PMID 21286371.

[ReferenceE-8] Pae CU, Patkar AA (February 2007). "Paroxetine: current status in psychiatry". Expert Review of Neurotherapeutics. 7 (2): 107–20. doi:10.1586/14737175.7.2.107. PMID 17286545.

[Preg2019-9] "Paroxetine Pregnancy and Breastfeeding Warnings" (in ଇଂରାଜୀ). Drugs.com. Archived from the original on 3 December 2018. Retrieved 3 March 2019.

[10] Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations – FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011) (in ଇଂରାଜୀ). DrugPatentWatch.com. p. 344. ISBN 9781934899816. Archived from the original on 2019-03-06. Retrieved 2019-03-04.

[BNF76-11] British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 363. ISBN 9780857113382.

[autogen1-12] British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 363. ISBN 9780857113382.

[NADAC2019-13] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ClinCalc_Top_300-14] "The Top 300 of 2020". ClinCalc. Archived from the original on 2020-03-18. Retrieved 11 April 2020.

[ClinCalc_Paroxetine-15] "Paroxetine - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.

[JusticeDept2July2012-16] "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data" (Press release). United States Department of Justice, Office of Public Affairs. 2 July 2012. Archived from the original on 9 September 2014. Retrieved 6 October 2015. The United States alleges that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy.

[ThomasNYT2July2012-17] Thomas, Katie; Schmidt, Michael S. (2 July 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times. Archived from the original on 2 March 2017. Retrieved 28 February 2017.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]

[୧୬]

[୧୭]